EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

How should medicines reimbursement work? The views of Spanish experts

Juan Carlos Rejon-Parrilla iD, David Epstein iD, Daniel Pérez-Troncoso, Jaime Espin

Health Economics, Policy and Law · 2025

DOI: 10.1017/s174413312400029x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Economics, Policy and Law, 2025. Verfasst von Juan Carlos Rejon-Parrilla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Technology Assessment Area (AETSA), Andalusian Public Foundation Progress and Health (FPS), Seville, Spain. Hauptthemen laut MEDLINE: Reimbursement Mechanisms, Insurance, Health, Reimbursement. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although the criteria that support reimbursement decisions for medicines are often set by legislation, as is the case in Spain, in many cases neither the definition nor the measurement methods for these criteria are provided. Our goal was to elicit the views of a large sample of Spanish technical specialists on how to evaluate each one of the criteria that inform pricing and reimbursement decisions in Spain. Professionals from various stakeholder groups involved in health economics, health technology assessment, and industry participated in a survey. Participants recommended that reimbursement decisions should take specific account of unmet medical need and rare diseases. Health benefit should be measured using quality-adjusted life-years. There should be an explicit cost-effectiveness threshold, and this threshold should take account of population groups and special situations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reimbursement MechanismsInsurance, Health, ReimbursementSpainHumansCost-Benefit AnalysisQuality-Adjusted Life YearsTechnology Assessment, BiomedicalSurveys and Questionnaires

Stichwörter der Autor:innen

health technology assessmentpharmaceutical policypricing and reimbursement

Autor:innen und Institutionen

  • Health Technology Assessment Area (AETSA), Andalusian Public Foundation Progress and Health (FPS), Seville, Spain.
  • Departamento de Economía Aplicada, Universidad de Granada, Campus de Cartuja, 18071, Granada, Spain.
  • Biostatistics and Modelling Department, Outcomes'10, Castellón de la Plana, Spain.
  • Andalusian School of Public Health, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs., Granada, Spain.
  • CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.

ORCID-Profile: Juan Carlos Rejon-Parrilla, David Epstein

Förderung

  • Ministerio de Ciencia e Innovación

Zitieren

APA

Rejon-Parrilla, J. C., Epstein, D., Pérez-Troncoso, D., & Espin, J. (2025). How should medicines reimbursement work? The views of Spanish experts. Health Economics, Policy and Law. https://doi.org/10.1017/s174413312400029x

Vancouver

Rejon-Parrilla JC, Epstein D, Pérez-Troncoso D, Espin J. How should medicines reimbursement work? The views of Spanish experts. Health Economics, Policy and Law. 2025. doi:10.1017/s174413312400029x

BibTeX
@article{RejonParrilla2025,
  author = {Rejon-Parrilla, Juan Carlos and Epstein, David and Pérez-Troncoso, Daniel and Espin, Jaime},
  title = {How should medicines reimbursement work? The views of Spanish experts},
  journal = {Health Economics, Policy and Law},
  year = {2025},
  doi = {10.1017/s174413312400029x}
}
Kostenlos starten →